評論
打印
But the sheer size of the deal elicited resistance.
但是該交易的絕對規模引發了抗議。
A group of shareholders led by Kazuhisa Takeda, a descendant of the founding family and a former board director,
以武田和久（創始家族的子孫兼前董事）為首的一群股東
and Shigeru Mishima, a former stockmarket analyst, was bitterly disappointed by this week's approval.
以及前股市分析師Shigeru Mishima對本周的批準感到心寒。
On the question of why the group opposed the acquisition, Mr Mishima cites "risk, risk, risk!".
關于他們為什么反對收購，Mishima先生引述，“風險，風險，風險！”
Local rivals, Astellas and Daiichi Sankyo, which have chosen to make smaller acquisitions, of American biotechnology companies,
當地競爭對手安斯泰來制藥和第一三共選擇了收購較小的美國生物技術公司
have seen their shares rise by 18% and 43% respectively, as Takeda's have fallen.
他們的股價分別增長18%和43%，而武田制藥則在下跌。
The dissidents may have a point. Scope for cost-cutting is relatively limited.
持異議者或許是有道理的。消減成本的前景相對有限。
It will saddle the combined entity with $48bn of net debt, or over five times its expected annual operating earnings.
公司將承擔合并實體480億美元的凈債務，或超過其預期年度營業收益的五倍。
To bring the huge cost of servicing this down, Mr Weber will have to dispose of promising products worth $5bn after the firms merge, on January 8th.
為了降低其巨大的成本，Weber先生將不得不在1月8日完成收購后，轉讓市場前景看好的產品，價值50億美元。
He claims strong combined cash-flow will help pay down debt quickly,
他宣稱強大的合并現金流將幫助迅速償還債務，
but Shire's haemophilia drugs, worth a quarter of its revenues in 2017, are threatened by new drugs from other big pharma firms.
但是夏爾的血友病藥物（該藥物在2017年占其收入的四分之一）受到了來自其他大型制藥商新型藥物的威脅。
Mr Takeda and other dissident shareholders do not deny the company needs to diversify its range of products.
武田先生和其他持異議的股東并不否認公司需要將產品范圍多樣化。
Nor, they claim, are they against acquisitions or globalisation. But the dose makes the poison. Swallowing Shire could prove toxic.
他們宣稱他們并非反對收購或全球化。但是劑量決定毒性。吞并夏爾可能證明是有毒的。
譯文由可可原創，僅供學習交流使用，未經許可請勿轉載。
